CD88, also known as C5a receptor (C5aR), is a G protein-coupled integral membrane protein. CD88, which is expressed on neutrophils, monocytes, macrophages, hepatocytes and mast cells, as well as on various epithelial and endothelial cells, serves as a receptor for the inflammatory peptide C5a. Research studies suggest a role for CD88 in the inflammatory response. The binding of C5a to CD88 has been shown to elicit increased production of acute phase proteins in liver. In brain, an increased production of CD88 has been shown to be associated with inflammation. Research also indicates a role for C5a/C5aR in the pathogenesis of rheumatoid arthritis, as well as a heightened responsiveness of human bronchial epithelial cells (HBECs) to C5a upon exposure of these cells to cigarette smoke and other environmental irritants.
CD88 Polyclonal Antibody detects endogenous levels of CD88 protein.
Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB: 1:500-1:2000, IHC-p: 1:100-1:300, IF: 1:200-1:1000, ELISA: 1:5000. Not yet tested in other applications.
CD88 Polyclonal Antibody product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.
Find more details at http://www.abbkine.com/product/cd88-polyclonal-antibody-abp50919.
bio-equip.cn
Abbkine Scientific Co., Ltd. was founded by a number of scientists and marketing experts in the field of life science in California in 2012. With growing demands from Asia Pacific, it move its headquarters to China. Combining cutting edge technology from United States with China's manufacturing engineering and cost advantages, we aim to provide innovative, high quality assay kits, recombinant proteins, antibodies and other research tools to accelerate life science fundamental research, drug discovery, etc.